<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35234271</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1791-3004</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Molecular medicine reports</Title><ISOAbbreviation>Mol Med Rep</ISOAbbreviation></Journal><ArticleTitle>Lack of an association between SCFD1 rs10139154 polymorphism and amyotrophic lateral sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">146</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3892/mmr.2022.12662</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease. Through a genome&#x2011;wide association study (GWAS), the Sec1 family domain&#x2011;containing protein&#xa0;1 (SCFD1) rs10139154 variant at 14q12 has emerged as a risk factor gene for ALS. Moreover, it has been reported to influence the age at onset (AAO) of patients with ALS. The aim of the present study was to assess the association of the SCFD1 rs10139154 polymorphism with the risk of developing ALS. For this purpose, 155&#xa0;patients with sporadic ALS and 155 healthy controls were genotyped for the SCFD1 rs10139154. The effect of the SCFD1 rs10139154 polymorphism was then examined on the following parameters: i)&#xa0;The risk of developing ALS; ii)&#xa0;the AAO of ALS; iii)&#xa0;the site of ALS onset (patients with bulbar onset ALS vs. healthy controls; and patients with limb onset ALS vs. healthy controls); and iv)&#xa0;the AAO of ALS onset with subgroup analyses based on the site of onset (bulbar and limb, crude and adjusted for sex). The analysis of all the outcomes was performed assuming five genetic models. Crude and adjusted analyses were applied. The threshold for statistical significance was set at 0.05. The results revealed no association between SCFD1 rs10139154 and any of the examined phenotypes in any of the models examined. On the whole, based on the findings of the present study, SCFD1 rs10139154 does not appear to play a determining role in the risk of developing ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Siokas</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aloizou</LastName><ForeName>Athina-Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liampas</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakirtzis</LastName><ForeName>Christos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>B' Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasios</LastName><ForeName>Grigorios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Speech and Language Therapy, University of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paterakis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University Hospital of Larissa, Medical School, University of Thessaly, 41100 Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sgantzos</LastName><ForeName>Markos</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogdanos</LastName><ForeName>Dimitrios P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, University General Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spandidos</LastName><ForeName>Demetrios A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsatsakis</LastName><ForeName>Aristidis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Toxicology, School of Medicine, University of Crete, 71003 Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitsias</LastName><ForeName>Panayiotis D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, University of Crete, 71003 Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dardiotis</LastName><ForeName>Efthimios</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Mol Med Rep</MedlineTA><NlmUniqueID>101475259</NlmUniqueID><ISSNLinking>1791-2997</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033942">Adaptor Proteins, Vesicular Transport</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C527528">SCFD1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D033942" MajorTopicYN="N">Adaptor Proteins, Vesicular Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Sec1 family domain&#x2011;containing protein 1</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">polymorphism</Keyword><Keyword MajorTopicYN="N">rs10139154</Keyword></KeywordList><CoiStatement>DAS is the Editor-in-Chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article. The other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>2</Day><Hour>8</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35234271</ArticleId><ArticleId IdType="pmc">PMC8915390</ArticleId><ArticleId IdType="doi">10.3892/mmr.2022.12662</ArticleId><ArticleId IdType="pii">146</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kojima Y, Kasai T, Noto YI, Ohmichi T, Tatebe H, Kitaoji T, Tsuji Y, Kitani-Morii F, Shinomoto M, Allsop D, et al. Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics. PLoS One. 2021;16:e0260323. doi: 10.1371/journal.pone.0260323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0260323</ArticleId><ArticleId IdType="pmc">PMC8629269</ArticleId><ArticleId IdType="pubmed">34843548</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjaly ZR, Scott KM, Abhinav K, Wijesekera L, Ganesalingam J, Goldstein LH, Janssen A, Dougherty A, Willey E, Stanton BR, et al. The sex ratio in amyotrophic lateral sclerosis: A population based study. Amyotroph Lateral Scler. 2010;11:439&#x2013;442. doi: 10.3109/17482961003610853.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482961003610853</ArticleId><ArticleId IdType="pmc">PMC6485484</ArticleId><ArticleId IdType="pubmed">20225930</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Boum&#xe9;diene F, Logroscino G, Couratier P, Babron MC, Leutenegger AL, Copetti M, Preux PM, Beghi E. Variation in worldwide incidence of amyotrophic lateral sclerosis: A meta-analysis. Int J Epidemiol. 2017;46:57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Przedborski S, Gordon PH, editors. Amyotrophic Lateral Sclerosis. CRC Press; 2005. p. p872.</Citation></Reference><Reference><Citation>Masrori P, Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur J Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedermeyer S, Murn M, Choi PJ. Respiratory failure in amyotrophic lateral sclerosis. Chest. 2019;155:401&#x2013;408. doi: 10.1016/j.chest.2018.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2018.06.035</ArticleId><ArticleId IdType="pubmed">29990478</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon YA, Fratta P, Traynor BJ, Chia R. The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci. 2020;14:42. doi: 10.3389/fnins.2020.00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00042</ArticleId><ArticleId IdType="pmc">PMC7012787</ArticleId><ArticleId IdType="pubmed">32116499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, Devenney EM, Strikwerda-Brown C, Hodges JR, Piguet O, Kiernan MC. Phenotypic variability in ALS-FTD and effect on survival. Neurology. 2020;94:e2005&#x2013;e2013. doi: 10.1212/WNL.0000000000009398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009398</ArticleId><ArticleId IdType="pubmed">32277059</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Schulte DJ, Ravits J. Neuropathology of amyotrophic lateral sclerosis and its variants. Neurol Clin. 2015;33:855&#x2013;876. doi: 10.1016/j.ncl.2015.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.012</ArticleId><ArticleId IdType="pmc">PMC4628785</ArticleId><ArticleId IdType="pubmed">26515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: Where are we now? Front Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E, Aloizou AM, Siokas V, Patrinos GP, Deretzi G, Mitsias P, Aschner M, Tsatsakis A. The role of MicroRNAs in patients with amyotrophic lateral sclerosis. J Mol Neurosci. 2018;66:617&#x2013;628. doi: 10.1007/s12031-018-1204-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-018-1204-1</ArticleId><ArticleId IdType="pubmed">30415446</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E, Siokas V, Sokratous M, Tsouris Z, Aloizou AM, Florou D, Dastamani M, Mentis AA, Brotis AG. Body mass index and survival from amyotrophic lateral sclerosis: A meta-analysis. Neurol Clin Pract. 2018;8:437&#x2013;444. doi: 10.1212/CPJ.0000000000000521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000000521</ArticleId><ArticleId IdType="pmc">PMC6276330</ArticleId><ArticleId IdType="pubmed">30564498</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.85</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Siokas V, Aloizou AM, Pateraki G. Chapter 21 - Toxicology of neurodegenerative diseases. In: Tsatsakis AM, editor. Toxicological Risk Assessment and Multi-System Health Impacts from Exposure. Academic Press; 2021. pp. 247&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-323-85215-9.00048-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E, Siokas V, Sokratous M, Tsouris Z, Michalopoulou A, Andravizou A, Dastamani M, Ralli S, Vinceti M, Tsatsakis A, Hadjigeorgiou GM. Genetic polymorphisms in amyotrophic lateral sclerosis: Evidence for implication in detoxification pathways of environmental toxicants. Environ Int. 2018;116:122&#x2013;135. doi: 10.1016/j.envint.2018.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envint.2018.04.008</ArticleId><ArticleId IdType="pubmed">29677557</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsatsakis AM, editor. Toxicological Risk Assessment and Multi-System Health Impacts from Exposure. Elsevier; 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-323-85215-9.00021-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S, Goizet C, Soulages A, Vallat JM, Masson GL. Genetics of amyotrophic lateral sclerosis: A review. J Neurol Sci. 2019;399:217&#x2013;226. doi: 10.1016/j.jns.2019.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.02.030</ArticleId><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: An update for 2018. Mayo Clin Proc. 2018;93:1617&#x2013;1628. doi: 10.1016/j.mayocp.2018.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.007</ArticleId><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HF, Wu ZY. Genotype-phenotype correlations of amyotrophic lateral sclerosis. Transl Neurodegener. 2016;5:3. doi: 10.1186/s40035-016-0050-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-016-0050-8</ArticleId><ArticleId IdType="pmc">PMC4738789</ArticleId><ArticleId IdType="pubmed">26843957</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M, Brown RH., Jr Genetics of amyotrophic lateral sclerosis. Cold Spring Harb Perspect Med. 2018;8:a024125. doi: 10.1101/cshperspect.a024125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024125</ArticleId><ArticleId IdType="pmc">PMC5932579</ArticleId><ArticleId IdType="pubmed">28270533</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou N, Yang Y, Scott IC, Lou X. The Sec domain protein Scfd1 facilitates trafficking of ECM components during chondrogenesis. Dev Biol. 2017;421:8&#x2013;15. doi: 10.1016/j.ydbio.2016.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2016.11.010</ArticleId><ArticleId IdType="pubmed">27851892</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamati P, Siokas V, Aloizou AM, Karampinis E, Arseniou S, Rakitskii VN, Tsatsakis A, Spandidos DA, Gozes I, Mitsias PD, et al. Does SCFD1 rs10139154 polymorphism decrease Alzheimer's disease risk? J Mol Neurosci. 2019;69:343&#x2013;350. doi: 10.1007/s12031-019-01363-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-019-01363-3</ArticleId><ArticleId IdType="pubmed">31267315</ArticleId></ArticleIdList></Reference><Reference><Citation>Bando Y, Katayama T, Taniguchi M, Ishibashi T, Matsuo N, Ogawa S, Tohyama M. RA410/Sly1 suppresses MPP+ and 6-hydroxydopamine-induced cell death in SH-SY5Y cells. Neurobiol Dis. 2005;18:143&#x2013;151. doi: 10.1016/j.nbd.2004.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2004.09.008</ArticleId><ArticleId IdType="pubmed">15649705</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr CM, Rizo J. At the junction of SNARE and SM protein function. Curr Opin Cell Biol. 2010;22:488&#x2013;495. doi: 10.1016/j.ceb.2010.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceb.2010.04.006</ArticleId><ArticleId IdType="pmc">PMC2923694</ArticleId><ArticleId IdType="pubmed">20471239</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, van der Spek RA, V&#xf5;sa U, de Jong S, Robinson MR, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016;48:1043&#x2013;1048. doi: 10.1038/ng.3622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3622</ArticleId><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zhou Q, Gu X, Wei Q, Cao B, Liu H, Hou Y, Shang H. An association study between SCFD1 rs10139154 variant and amyotrophic lateral sclerosis in a Chinese cohort. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:413&#x2013;418. doi: 10.1080/21678421.2017.1418006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1418006</ArticleId><ArticleId IdType="pubmed">29260601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, Shefner J, WFN Research Group On ALS/MND A revision of the El Escorial criteria-2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:291&#x2013;292. doi: 10.3109/21678421.2015.1049183.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1049183</ArticleId><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E, Karampinis E, Siokas V, Aloizou AM, Rikos D, Ralli S, Papadimitriou D, Bogdanos DP, Hadjigeorgiou GM. ERCC6L2 rs591486 polymorphism and risk for amyotrophic lateral sclerosis in Greek population. Neurol Sci. 2019;40:1237&#x2013;1244. doi: 10.1007/s10072-019-03825-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03825-3</ArticleId><ArticleId IdType="pubmed">30879219</ArticleId></ArticleIdList></Reference><Reference><Citation>Siokas V, Aloizou AM, Liampas I, Tsouris Z, Mentis AA, Nasios G, Papadimitriou D, Bogdanos DP, Hadjigeorgiou GM, Dardiotis E. Lack of association between TREM2 rs75932628 variant and amyotrophic lateral sclerosis. Mol Biol Rep. 2021;48:2601&#x2013;2610. doi: 10.1007/s11033-021-06312-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-021-06312-1</ArticleId><ArticleId IdType="pubmed">33826063</ArticleId></ArticleIdList></Reference><Reference><Citation>Siokas V, Karampinis E, Aloizou AM, Mentis AA, Liakos P, Papadimitriou D, Liampas I, Nasios G, Bogdanos DP, Hadjigeorgiou GM, Dardiotis E. CYP1A2 rs762551 polymorphism and risk for amyotrophic lateral sclerosis. Neurol Sci. 2021;42:175&#x2013;182. doi: 10.1007/s10072-020-04535-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04535-x</ArticleId><ArticleId IdType="pubmed">32592103</ArticleId></ArticleIdList></Reference><Reference><Citation>Liampas I, Siokas V, Aloizou AM, Bakirtzis C, Tsouris Z, Nousia A, Nasios G, Papadimitriou D, Liakos P, Bogdanos DP, et al. MOBP rs616147 polymorphism and risk of amyotrophic lateral sclerosis in a greek population: A case-control study. Medicina (Kaunas) 2021;57:1337. doi: 10.3390/medicina57121337.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57121337</ArticleId><ArticleId IdType="pmc">PMC8708438</ArticleId><ArticleId IdType="pubmed">34946282</ArticleId></ArticleIdList></Reference><Reference><Citation>Siokas V, Kardaras D, Aloizou AM, Asproudis I, Boboridis KG, Papageorgiou E, Hadjigeorgiou GM, Tsironi EE, Dardiotis E. BDNF rs6265 (Val66Met) polymorphism as a risk factor for blepharospasm. Neuromolecular Med. 2019;21:68&#x2013;74. doi: 10.1007/s12017-018-8519-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-018-8519-5</ArticleId><ArticleId IdType="pubmed">30519954</ArticleId></ArticleIdList></Reference><Reference><Citation>Siokas V, Aslanidou P, Aloizou AM, Peristeri E, Stamati P, Liampas I, Arseniou S, Drakoulis N, Aschner M, Tsatsakis A, et al. Does the CD33 rs3865444 polymorphism confer susceptibility to Alzheimer's disease? J Mol Neurosci. 2020;70:851&#x2013;860. doi: 10.1007/s12031-020-01507-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-020-01507-w</ArticleId><ArticleId IdType="pubmed">32088842</ArticleId></ArticleIdList></Reference><Reference><Citation>Sol&#xe9; X, Guin&#xf3; E, Valls J, Iniesta R, Moreno V. SNPStats: A web tool for the analysis of association studies. Bioinformatics. 2006;22:1928&#x2013;1929. doi: 10.1093/bioinformatics/btl268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btl268</ArticleId><ArticleId IdType="pubmed">16720584</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45:580&#x2013;585. doi: 10.1038/ng.2653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2653</ArticleId><ArticleId IdType="pmc">PMC4010069</ArticleId><ArticleId IdType="pubmed">23715323</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A, Fogh I, Selvackadunco S, Topp SD, Shatunov A, van Rheenen W, Al-Khleifat A, Opie-Martin S, Ratti A, Calvo A, et al. SCFD1 expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressed. Brain Commun. 2021;3:fcab236. doi: 10.1093/braincomms/fcab236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab236</ArticleId><ArticleId IdType="pmc">PMC8545614</ArticleId><ArticleId IdType="pubmed">34708205</ArticleId></ArticleIdList></Reference><Reference><Citation>Keon M, Musrie B, Dinger M, Brennan SE, Santos J, Saksena NK. Destination amyotrophic lateral sclerosis. Front Neurol. 2021;12:596006. doi: 10.3389/fneur.2021.596006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.596006</ArticleId><ArticleId IdType="pmc">PMC8039771</ArticleId><ArticleId IdType="pubmed">33854469</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Talbot K, McDermott CJ, Hardiman O, Shefner JM, Al-Chalabi A, Huynh W, Cudkowicz M, Talman P, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17:104&#x2013;118. doi: 10.1038/s41582-020-00434-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado DA, Davidson BL. Gene therapy for ALS: A review. Mol Ther. 2021;29:3345&#x2013;3358. doi: 10.1016/j.ymthe.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan W, Beaulieu-Jones BK, Yu KH, Lipnick SL, Palmer N, Loscalzo J, Cai T, Kohane IS. Temporal bias in case-control design: Preventing reliable predictions of the future. Nat Commun. 2021;12:1107. doi: 10.1038/s41467-021-21390-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21390-2</ArticleId><ArticleId IdType="pmc">PMC7889612</ArticleId><ArticleId IdType="pubmed">33597541</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>